Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01907165 · ClinicalTrials.gov registry record · Early Phase 1
Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide
A Early Phase 1 study of Glioblastoma, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT01907165 is a Early Phase 1 study of Glioblastoma that has completed, run by Washington University School of Medicine. The registered enrollment target is 21 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01907165, a Early Phase 1 study of Glioblastoma, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies disulfiram in treating patients with glioblastoma multiforme (GBM) who have completed radiation therapy with temozolomide. Disulfiram may block some of the enzymes needed for tumor cell growth and improve clinical outcome in GBM patients.
Conditions Studied
Interventions
- DRUG Temozolomide
- DRUG Disulfiram
- DIETARY_SUPPLEMENT Copper gluconate
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2013-10-10 |
| Est. Completion | 2018-02-09 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01907165
The ClinicalTrials.gov registry entry for NCT01907165 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (81% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 3 interventions - of which Temozolomide is the first listed.
NCT01907165 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT01907165 about?
NCT01907165 is a clinical study titled "Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide". This clinical trial studies disulfiram in treating patients with glioblastoma multiforme (GBM) who have completed radiation therapy with temozolomide. Disulfiram may block some of the enzymes needed for tumor cell growth and improve clinical outcome in GBM patients.
What is the current status of trial NCT01907165?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 21 participants. The study started on 2013-10-10. Estimated completion is 2018-02-09.
What conditions does trial NCT01907165 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT01907165?
The interventions under investigation include: Temozolomide (DRUG), Disulfiram (DRUG), Copper gluconate (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01907165?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01907165 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
RECRUITING · Early Phase 1
-
Implantable Microdevice In Primary Brain Tumors
RECRUITING · Early Phase 1
-
A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions
RECRUITING · Early Phase 1
-
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
RECRUITING · Early Phase 1
-
Neoadjuvant Chemoradiotherapy With or Without Concurrent Azeliragon in Patients With Newly Diagnosed Glioblastoma
RECRUITING · Early Phase 1
-
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.